4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, has announced that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of US$16.00 per share. In addition, 4D Molecular Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be US$120.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by 4D Molecular Therapeutics. The offering is expected to close on May 9, 2023, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP advised 4D Molecular Therapeutics in the offering, with a corporate deal team led by Bay Area partners Mark Roeder and Phillip Stoup, with associates Zuzanna Gruca, Raul Gonzalez, and Chelsi DeTurk. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings; on data privacy matters by Bay Area partner Heather Deixler; on tax matters by Bay Area partner Grace Lee; and on benefits and compensation matters by Bay Area partner Maj Vaseghi.